Uso ottimale del docetaxel nella chemioterapia adiuvante delle pazienti con carcinoma mammario HER2-negativo

Translated title of the contribution: Optimal role of docetaxel in adjuvant chemotherapy for early stage HER2-negative breast cancer

S. I S Fattoruso, S. Rossi, P. Vici, F. Di Filippo, C. Botti, L. Di Lauro, P. Foggi, E. Saracca, F. R. Ferranti, P. Visca, M. Lopez

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The fundamental imperative of adjuvant treatment of early breast cancer is to improve long-term survival and minimize toxicity. The inclusion of docetaxel in adjuvant chemotherapy regimens has improved patient survival in comparison to anthracycline-containing regimens, even if the incidence of acute side effects has increased in some studies. However, late or persistent toxic effects are becoming more important due to an increasing proportion of patients remaining disease free after treatment for early breast cancer. Several studies have recently reported that docetaxel-containing regimens without anthracyclines are equally active, and have no apparent cardiotoxicity. At present, docetaxel-based combinations represent an appropriate choice in the adjuvant treatment of HER2-negative breast cancer, and several studies are ongoing aiming at a better evaluation of the efficacy of this agent in order to optimize its role.

Original languageItalian
Pages (from-to)443-447
Number of pages5
JournalClinica Terapeutica
Volume159
Issue number6
Publication statusPublished - Nov 2008

Fingerprint

docetaxel
Adjuvant Chemotherapy
Anthracyclines
Breast Neoplasms
Survival
Poisons
Therapeutics
Incidence

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Fattoruso, S. I. S., Rossi, S., Vici, P., Di Filippo, F., Botti, C., Di Lauro, L., ... Lopez, M. (2008). Uso ottimale del docetaxel nella chemioterapia adiuvante delle pazienti con carcinoma mammario HER2-negativo. Clinica Terapeutica, 159(6), 443-447.

Uso ottimale del docetaxel nella chemioterapia adiuvante delle pazienti con carcinoma mammario HER2-negativo. / Fattoruso, S. I S; Rossi, S.; Vici, P.; Di Filippo, F.; Botti, C.; Di Lauro, L.; Foggi, P.; Saracca, E.; Ferranti, F. R.; Visca, P.; Lopez, M.

In: Clinica Terapeutica, Vol. 159, No. 6, 11.2008, p. 443-447.

Research output: Contribution to journalArticle

Fattoruso, SIS, Rossi, S, Vici, P, Di Filippo, F, Botti, C, Di Lauro, L, Foggi, P, Saracca, E, Ferranti, FR, Visca, P & Lopez, M 2008, 'Uso ottimale del docetaxel nella chemioterapia adiuvante delle pazienti con carcinoma mammario HER2-negativo', Clinica Terapeutica, vol. 159, no. 6, pp. 443-447.
Fattoruso SIS, Rossi S, Vici P, Di Filippo F, Botti C, Di Lauro L et al. Uso ottimale del docetaxel nella chemioterapia adiuvante delle pazienti con carcinoma mammario HER2-negativo. Clinica Terapeutica. 2008 Nov;159(6):443-447.
Fattoruso, S. I S ; Rossi, S. ; Vici, P. ; Di Filippo, F. ; Botti, C. ; Di Lauro, L. ; Foggi, P. ; Saracca, E. ; Ferranti, F. R. ; Visca, P. ; Lopez, M. / Uso ottimale del docetaxel nella chemioterapia adiuvante delle pazienti con carcinoma mammario HER2-negativo. In: Clinica Terapeutica. 2008 ; Vol. 159, No. 6. pp. 443-447.
@article{2da6d75c494c451e96f5caea7aecb569,
title = "Uso ottimale del docetaxel nella chemioterapia adiuvante delle pazienti con carcinoma mammario HER2-negativo",
abstract = "The fundamental imperative of adjuvant treatment of early breast cancer is to improve long-term survival and minimize toxicity. The inclusion of docetaxel in adjuvant chemotherapy regimens has improved patient survival in comparison to anthracycline-containing regimens, even if the incidence of acute side effects has increased in some studies. However, late or persistent toxic effects are becoming more important due to an increasing proportion of patients remaining disease free after treatment for early breast cancer. Several studies have recently reported that docetaxel-containing regimens without anthracyclines are equally active, and have no apparent cardiotoxicity. At present, docetaxel-based combinations represent an appropriate choice in the adjuvant treatment of HER2-negative breast cancer, and several studies are ongoing aiming at a better evaluation of the efficacy of this agent in order to optimize its role.",
keywords = "Adjuvant chemotherapy, Breast cancer, Docetaxel, HER2",
author = "Fattoruso, {S. I S} and S. Rossi and P. Vici and {Di Filippo}, F. and C. Botti and {Di Lauro}, L. and P. Foggi and E. Saracca and Ferranti, {F. R.} and P. Visca and M. Lopez",
year = "2008",
month = "11",
language = "Italian",
volume = "159",
pages = "443--447",
journal = "Clinica Terapeutica",
issn = "0009-9074",
publisher = "Societa Editrice Universo",
number = "6",

}

TY - JOUR

T1 - Uso ottimale del docetaxel nella chemioterapia adiuvante delle pazienti con carcinoma mammario HER2-negativo

AU - Fattoruso, S. I S

AU - Rossi, S.

AU - Vici, P.

AU - Di Filippo, F.

AU - Botti, C.

AU - Di Lauro, L.

AU - Foggi, P.

AU - Saracca, E.

AU - Ferranti, F. R.

AU - Visca, P.

AU - Lopez, M.

PY - 2008/11

Y1 - 2008/11

N2 - The fundamental imperative of adjuvant treatment of early breast cancer is to improve long-term survival and minimize toxicity. The inclusion of docetaxel in adjuvant chemotherapy regimens has improved patient survival in comparison to anthracycline-containing regimens, even if the incidence of acute side effects has increased in some studies. However, late or persistent toxic effects are becoming more important due to an increasing proportion of patients remaining disease free after treatment for early breast cancer. Several studies have recently reported that docetaxel-containing regimens without anthracyclines are equally active, and have no apparent cardiotoxicity. At present, docetaxel-based combinations represent an appropriate choice in the adjuvant treatment of HER2-negative breast cancer, and several studies are ongoing aiming at a better evaluation of the efficacy of this agent in order to optimize its role.

AB - The fundamental imperative of adjuvant treatment of early breast cancer is to improve long-term survival and minimize toxicity. The inclusion of docetaxel in adjuvant chemotherapy regimens has improved patient survival in comparison to anthracycline-containing regimens, even if the incidence of acute side effects has increased in some studies. However, late or persistent toxic effects are becoming more important due to an increasing proportion of patients remaining disease free after treatment for early breast cancer. Several studies have recently reported that docetaxel-containing regimens without anthracyclines are equally active, and have no apparent cardiotoxicity. At present, docetaxel-based combinations represent an appropriate choice in the adjuvant treatment of HER2-negative breast cancer, and several studies are ongoing aiming at a better evaluation of the efficacy of this agent in order to optimize its role.

KW - Adjuvant chemotherapy

KW - Breast cancer

KW - Docetaxel

KW - HER2

UR - http://www.scopus.com/inward/record.url?scp=58849094087&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58849094087&partnerID=8YFLogxK

M3 - Articolo

C2 - 19169606

AN - SCOPUS:58849094087

VL - 159

SP - 443

EP - 447

JO - Clinica Terapeutica

JF - Clinica Terapeutica

SN - 0009-9074

IS - 6

ER -